Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that
β-amyloid (Aβ) is an important marker for the diagnosis of AD. 18F-92 molecular probe is a
novel molecularly targeted imaging agent, which can rapidly penetrate the blood-brain barrier
and has high affinity and selectivity for Aβ protein. In this study, 18F-92 PET/CT was used
to monitor the regional distribution and the degree of deposition in patients with
Alzheimer's disease, and compared with clinical symptoms (neuropsychometry) to evaluate its
application value in the diagnosis of AD.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University